AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) (Brand name: Datverzo) which is a new drug in India.

Through this approval, Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) (Brand name: Datverzo) in India for the specified indication, subject to the receipt of related statutory approvals, if any.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 9025.80 as compared to the previous close of Rs. 9011.85. The total number of shares traded during the day was 57 in over 26 trades.

The stock hit an intraday high of Rs. 9057.40 and intraday low of 8950.20. The net turnover during the day was Rs. 513568.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Pharmaceuticals CDSCO Permission DatopotamabDeruxtecan Powder